Tags

Type your tag names separated by a space and hit enter

Glycogen synthase kinase 3: a drug target for CNS therapies.
J Neurochem. 2004 Jun; 89(6):1313-7.JN

Abstract

Abstract Glycogen synthase kinase3 (GSK3) is emerging as a prominent drug target in the CNS. The most exciting of the possibilities of GSK3 lies within the treatment of Alzheimer's disease (AD) where abnormal increases in GSK3 levels and activity have been associated with neuronal death, paired helical filament tau formation and neurite retraction as well as a decline in cognitive performance. Abnormal activity of GSK3 is also implicated in stroke. Lithium, a widely used drug for affective disorders, inhibits GSK3 at therapeutically relevant concentrations. Thus while the rationale remains testable, pharmaceutical companies are investing in finding a selective inhibitor of GSK3. In the present review, we summarize the properties of GSK3, and discuss the potential for such a therapy in AD, and other CNS disorders.

Authors+Show Affiliations

Bhat RV
AstraZeneca R & D, Södertälje, B213:231B, Sweden 151-85. Ratan.Bhat@astrazeneca.com
Budd Haeberlein SL
No affiliation info available
Avila J
No affiliation info available

MeSH

Alzheimer DiseaseAnimalsCentral Nervous System DiseasesEnzyme InhibitorsGlycogen Synthase Kinase 3HumansInsulin ResistanceLithiumNeuronal PlasticityNeuronsPhosphorylation

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15189333

Citation

Bhat, Ratan V., et al. "Glycogen Synthase Kinase 3: a Drug Target for CNS Therapies." Journal of Neurochemistry, vol. 89, no. 6, 2004, pp. 1313-7.
Bhat RV, Budd Haeberlein SL, Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem. 2004;89(6):1313-7.
Bhat, R. V., Budd Haeberlein, S. L., & Avila, J. (2004). Glycogen synthase kinase 3: a drug target for CNS therapies. Journal of Neurochemistry, 89(6), 1313-7.
Bhat RV, Budd Haeberlein SL, Avila J. Glycogen Synthase Kinase 3: a Drug Target for CNS Therapies. J Neurochem. 2004;89(6):1313-7. PubMed PMID: 15189333.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Glycogen synthase kinase 3: a drug target for CNS therapies. AU - Bhat,Ratan V, AU - Budd Haeberlein,Samantha L, AU - Avila,Jesús, PY - 2004/6/11/pubmed PY - 2004/7/23/medline PY - 2004/6/11/entrez SP - 1313 EP - 7 JF - Journal of neurochemistry JO - J Neurochem VL - 89 IS - 6 N2 - Abstract Glycogen synthase kinase3 (GSK3) is emerging as a prominent drug target in the CNS. The most exciting of the possibilities of GSK3 lies within the treatment of Alzheimer's disease (AD) where abnormal increases in GSK3 levels and activity have been associated with neuronal death, paired helical filament tau formation and neurite retraction as well as a decline in cognitive performance. Abnormal activity of GSK3 is also implicated in stroke. Lithium, a widely used drug for affective disorders, inhibits GSK3 at therapeutically relevant concentrations. Thus while the rationale remains testable, pharmaceutical companies are investing in finding a selective inhibitor of GSK3. In the present review, we summarize the properties of GSK3, and discuss the potential for such a therapy in AD, and other CNS disorders. SN - 0022-3042 UR - https://www.unboundmedicine.com/medline/citation/15189333/Glycogen_synthase_kinase_3:_a_drug_target_for_CNS_therapies_ DB - PRIME DP - Unbound Medicine ER -